Q-omics provides the consensus-scored RAPGEF4-AS1 profile across patient tissues and cancer cell-line models. RAPGEF4-AS1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RAPGEF4-AS1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, RAPGEF4-AS1 RNA expression shows 14,579 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KIRC, and THYM as cancer lineages where RAPGEF4-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAPGEF4-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAPGEF4-AS1 survival associations across molecular data types. RAPGEF4-AS1 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAPGEF4-AS1 RNA expression–survival associations across cancer types. High RAPGEF4-AS1 expression shows unfavorable associations in MESO, KIRP, KICH, UCEC and UVM, but favorable associations in READ. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for RAPGEF4-AS1 RNA expression.
This table summarizes RAPGEF4-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RAPGEF4-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAPGEF4-AS1 shows lower tumor expression in BRCA and higher tumor expression in KIRC, HNSC, KIRP, LUSC and LIHC. The KIRC box plot shows higher RAPGEF4-AS1 RNA expression in tumor versus normal tissue (log2 FC = +0.016, t-test p < 0.001).
This table shows molecular features associated with RAPGEF4-AS1 in patient tissues and cancer cell lines. In patient samples, RAPGEF4-AS1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
